ALPINE IMMUNE SCIENCES INC (ALPN)
US02083G1004 - Common Stock
| MRQ (2024-3-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 33.02M | 43.92M | 13.40M | 67.90M | 35.00M | |||
| Marketable Securities | 272.65M | 283.49M | 224.30M | 94.40M | 70.60M | |||
| Receivables | 543.00K | 749.00K | 700.00K | 25.30M | 400.00K | |||
| Other Current Assets | 2.05M | 1.87M | 2.60M | 4.40M | 1.10M | |||
| Total Current Assets | 308.25M | 330.03M | 241.00M | 192.00M | 107.10M | |||
| Non-Current Assets | ||||||||
| PPE Net | 8.67M | 8.99M | 9.80M | 10.60M | 11.20M | |||
| Investments And Advances | 56.45M | 40.56M | 35.50M | 52.90M | 25.50M | |||
| Intangibles | N/A | N/A | N/A | N/A | N/A | |||
| Other Non-Current Assets | 269.00K | 268.00K | 400.00K | 500.00K | 300.00K | |||
| Total Non-Current Assets | 65.39M | 49.82M | 45.70M | 63.90M | 37.00M | |||
| TOTAL ASSETS | 373.65M | 379.85M | 286.70M | 255.90M | 144.10M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | 0.00 | 3.40M | 4.60M | 2.50M | |||
| Accrued Expenses | 17.84M | 22.10M | 14.80M | 10.00M | 6.40M | |||
| Accounts Payable | 4.17M | 3.59M | 4.30M | 3.30M | 600.00K | |||
| Other Current Liabilities | 10.23M | 16.29M | 35.60M | 51.80M | 31.60M | |||
| Total Current Liabilities | 32.24M | 41.98M | 58.00M | 69.80M | 41.20M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 3.40M | 7.60M | |||
| Deferred Taxes/Income | N/A | N/A | N/A | N/A | N/A | |||
| Other Non-Current Liabilities | 8.71M | 9.93M | 49.30M | 61.80M | 33.20M | |||
| Total Non-Current Liabilities | 8.71M | 9.93M | 49.30M | 65.20M | 40.70M | |||
| TOTAL LIABILITIES | 40.94M | 51.91M | 107.30M | 135.00M | 81.90M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -274.06M | -256.14M | -224.00M | -166.20M | -115.90M | |||
| Additional Paid In Capital | 606.96M | 583.63M | 404.50M | 287.30M | 177.90M | |||
| Common Shares | 66.00K | 60.00K | 0.00 | 0.00 | 0.00 | |||
| Treasury Stock | N/A | N/A | 0.00 | 0.00 | 0.00 | |||
| Other Shareholders' Equity | -263.00K | 397.00K | -1.10M | -300.00K | 100.00K | |||
| Shares Outstanding | 65.55M | 60.35M | 46.00M | 30.20M | 23.80M | |||
| Tangible Book Value per Share | 5.08 | 5.43 | 3.90 | 4.00 | 2.61 | |||
| Total Shareholders' Equity | 332.70M | 327.94M | 179.40M | 120.90M | 62.20M | |||
| TOTAL LIABILITIES AND EQUITY | 373.65M | 379.85M | 286.70M | 255.90M | 144.10M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | 0.03 | 0.12 | |||
| Current Ratio | 9.56 | 7.86 | 4.16 | 2.75 | 2.60 | |||
| Return On Assets (ROA) | -9.86% | -8.47% | -20.15% | -19.67% | -19.39% | |||
| Return On Equity (ROE) | -11.07% | -9.81% | -32.20% | -41.63% | -44.92% | |||
All data in USD